Aurinia Pharmaceuticals (AUPH) EBT Margin (2019 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly EBT Margin came in at 56.53% in Q1 2026, up 1755.0% YoY from 3.05% in Q1 2025, and up 22.14% on a QoQ basis from 46.28% in Q4 2025.
Aurinia Pharmaceuticals (AUPH) EBT Margin (2019 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 8 years of EBT Margin data on file, last reported at 56.53% in Q1 2026.
- Quarterly EBT Margin rose 1755.0% year-over-year to 56.53% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 44.83% (up 2793.0% YoY) and the FY2025 annual result came in at 40.33%, up 3716.0% from the prior year.
- EBT Margin grew to 56.53% in Q1 2026, from 46.28% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 56.53% in Q1 2026 to a low of 173.97% in Q1 2022.
- A 5-year average of 21.55% and a median of 14.41% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin jumped 533709 bps — and 2023, when it sank 971 bps.
- Tracing AUPH's EBT Margin over 5 years: stood at 88.59% in 2022, then soared by 34 bps to 58.58% in 2023, then surged by 103 bps to 1.96% in 2024, then soared by 2262 bps to 46.28% in 2025, then gained by 22 bps to 56.53% in 2026.
- The last three EBT Margin figures came in at 56.53% (Q1 2026), 46.28% (Q4 2025), and 43.5% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 58.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 58.62% |
| Mar 31, 2026 | 56.53% |
| Dec 31, 2025 | 46.28% |
| Sep 30, 2025 | 43.50% |
| Jun 30, 2025 | 31.65% |
| Mar 31, 2025 | 38.98% |
| Dec 31, 2024 | 1.96% |
| Sep 30, 2024 | 21.85% |
| Jun 30, 2024 | 2.58% |
| Mar 31, 2024 | -19.90% |
| Dec 31, 2023 | -58.58% |
| Sep 30, 2023 | -24.12% |
| Jun 30, 2023 | -29.24% |
| Mar 31, 2023 | -74.89% |
| Dec 31, 2022 | -88.59% |
| Sep 30, 2022 | -14.41% |
| Jun 30, 2022 | -125.95% |
| Mar 31, 2022 | -173.97% |
| Dec 31, 2021 | -139.28% |
| Sep 30, 2021 | -342.59% |